Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women

Bjarnason, 1996, Tibolone, J Clin Endocrinol Metab, 81, 2419, 10.1210/jc.81.7.2419 Bjarnason, 1997, The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women, Bone, 20, 151, 10.1016/S8756-3282(96)00335-3 Bjarnason, N. H., Byrjalsen, I., Hassager, C., Haarbo, J., and Christiansen, C. Low dose estradiol in combination with gestodene is fully preventive in early postmenopausal women. Am J Obstet Gynecol. In press. Bonde, 1995, Applications of an enzyme immuno assay for a new markers of bone resorption (CrossLaps), J Clin Endocrinol Metab, 80, 864, 10.1210/jc.80.3.864 Chesnut, 1997, Hormone replacement therapy in postmenopausal women, Am J Med, 102, 29, 10.1016/S0002-9343(96)00387-7 Christiansen, 1982, Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women, J Clin Endocrinol Metab, 55, 1124, 10.1210/jcem-55-6-1124 Christiansen, 1981, Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy, Lancet, 1, 459, 10.1016/S0140-6736(81)91848-1 Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 7:1–6; 1997. Delmas, 1997, The effects of raloxifene on bone mineral density, serum cholesterol and uterine endometrium in postmenopausal women, N Engl J Med, 337, 1641, 10.1056/NEJM199712043372301 Garnero, 1999, A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover, Bone, 24, 603, 10.1016/S8756-3282(99)00087-3 Garnero, 1994, Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J Clin Endocrinol Metab, 79, 1693, 10.1210/jc.79.6.1693 Genant, 1996, Noninvasive assessment of bone mineral and structure, J Bone Miner Res, 11, 707, 10.1002/jbmr.5650110602 Greenspan, 1998, Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women, J Bone Miner Res, 13, 1431, 10.1359/jbmr.1998.13.9.1431 Herd, 1997, The prevention of early postmenopausal bone loss by cyclical etidronate therapy, Am J Med, 103, 92, 10.1016/S0002-9343(97)00019-3 Hosking, 1998, Prevention of bone loss with alendronate in postmenopausal women under 60 years of age, N Engl J Med, 338, 485, 10.1056/NEJM199802193380801 Little, 1988, Relationship of glycosylated hemoglobin to oral glucose tolerance. Implications for diabetes screening, Diabetes, 37, 60, 10.2337/diabetes.37.1.60 Mortensen, 1998, Risedronate increases bone mass in an early postmenopausal population, J Clin Endocrinol Metab, 83, 396, 10.1210/jc.83.2.396 Peters, 1996, A clinical approach for the diagnosis of diabetes mellitus, JAMA, 276, 1246, 10.1001/jama.276.15.1246 Ravn, 1998, Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment, Bone, 22, 559, 10.1016/S8756-3282(98)00044-1 Ravn, 1999, Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women, Bone, 24, 237, 10.1016/S8756-3282(98)00183-5 Ravn, 1996, The effect on bone mass and bone markers of different doses of ibandronate, Bone, 19, 527, 10.1016/S8756-3282(96)00229-3 Ravn, P., Hosking, D., Thompson, D., Cizza, G., McClung, M., Yates, A. J., Bjarnason, N. H., and Christiansen, C., for the EPIC Study Group. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort (EPIC) study. J Clin Endocrinol Metab. In press. Ravnikar, V. A. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventive health benefits? Womens Health Issues 2:75–80, discussion 80–82; 1992. Riis, 1995, Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy, Osteopor Int, 5, 276, 10.1007/BF01774018 Rosen, 1997, The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation, J Clin Endocrinol Metab, 82, 1904, 10.1210/jc.82.6.1904 Rosen, 1998, Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates, Calcif Tissue Int, 63, 363, 10.1007/s002239900541 Rosenquist, 1998, Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen, Clin Chem, 44, 2281, 10.1093/clinchem/44.11.2281 Rosenquist, 1995, Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies, Clin Chem, 41, 1439, 10.1093/clinchem/41.10.1439 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6